



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/799,299	03/12/2004	Gerald Horn	114309-1017	7833
7590	12/31/2009			
BELL, BOYD & LLOYD LLC P.O. Box 1135 Chicago, IL 60690-1135				EXAMINER HAND, MELANIE JO
ART UNIT 3761		PAPER NUMBER		
MAIL DATE 12/31/2009		DELIVERY MODE PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/799,299	HORN, GERALD	
	<b>Examiner</b>	<b>Art Unit</b>	
	MELANIE J. HAND	3761	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 18 September 2009.

2a) This action is **FINAL**.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 33-36 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 33-36 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>9/18/09</u> .	6) <input type="checkbox"/> Other: _____ .

**DETAILED ACTION**

***Response to Arguments***

1. Applicant's arguments filed September 18, 2009 have been fully considered but they are not persuasive. The arguments in their entirety have been previously addressed in the non-final action mailed March 19, 2009 and therefore they will not be addressed again herein. The arguments were and are not persuasive and therefore the rejections have been maintained.

***Information Disclosure Statement***

2. The information disclosure statement (IDS) submitted on September 18, 2009 was filed after the mailing date of the non-final action on March 19, 2009. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 33-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gluchowski (U.S. Patent No. 5,252,295) in view of Gerstenberg et al (U.S. Patent No. 5,236,904).

With respect to **claim 33**: Gluchowski teaches an ophthalmic formulation, comprising: a sterile aqueous carrier in the form of saline; and a pharmaceutically active compound consisting essentially of an imidazoline in a therapeutically effective amount. (Col. 4, lines 5-8, 15-20) The limitation “to contract a pupil of a human patient's eye in dim light so that the pupil is effectively reduced to improve vision in dim light and further to minimize eye redness” constitutes functional language that is given little patentable weight herein.

Gluchowski does not teach a pharmaceutically active compound consisting essentially of phentolamine. Applicant states in the Specification that alpha 1 antagonists such as phentolamine that are used to treat sexual dysfunction (interpreted herein as “those known in the art for treating sexual dysfunction”) can be used as the claimed pharmaceutically active compound of the claimed invention. (Specification, Page 3, line 29 – Page 4, line 4) This constitutes an admission by applicant that not only is the use of phentolamine known, its use in the art of treatments of sexual dysfunction is also known. Gerstenberg discloses such use of phentolamine in a sexual dysfunction treatment compound, and therefore according to applicant's admission, if used as the imidazoline in the compound of Gluchowski, will yield a formulation identical to that disclosed by applicant and therefore inherently provide the benefits of pupil contraction/reduction to improve vision in dim light and further reduce redness. Thus although neither Gluchowski nor Gerstenberg explicitly meets the functional limitations pertaining to pupil contraction, reduction to improve vision or redness, it would be obvious to one of ordinary skill in the art to modify the formulation of Gluchowski such that the imidazoline is phentolamine with a reasonable expectation of success, as phentolamine as an alpha 1 receptor antagonist controls the degree of iris dilation (or contraction in environments with less light), which results in control of pupil contraction.

With respect to **claim 34**: Gluchowski teaches that the active agent is present in an amount between 0.0001-1% weight by volume solvent (g/cc). Gluchowski teaches a composition having 300 ml water, therefore the active agent is present in an amount between 30-3,000 mg/cc, which overlaps the range set forth in claim 34. (Col. 4, lines 20-25, Col. 12, lines 48-50)

With respect to **claim 35**: The sterile aqueous carrier taught by Gluchowski comprises saline, which is an ophthalmic artificial tear solution. (Col. 4, lines 5-7)

With respect to **claim 36**: The formulation fairly suggested by Gluchowski meets all of the remaining claim limitations of claim 36. With respect to the limitation “the pupil is effectively reduced by 1.0 mm or more”, this limitation is rendered obvious by Gluchowski because the formulation consisting essentially of phentolamine that is fairly suggested by Gluchowksi will necessarily meet this limitation by virtue of meeting all of the other claim limitations as to the claimed formulation. The motivation to modify the formulation so as to consist essentially of phentolamine is stated *supra* with respect to claim 33.

### **Conclusion**

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELANIE J. HAND whose telephone number is (571)272-6464. The examiner can normally be reached on Mon-Thurs 8:00-5:30, alternate Fridays 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tatyana Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Melanie J Hand/  
Primary Examiner, Art Unit 3761